Your Brain, Your Bones, and Your Voice — All Changing at Once

Episode Script

Thanks Toni. We've got a good one today — three studies, all dropped basically the same week, all pointing at parts of menopause that don't get nearly enough airtime.

Let's start with bones.

Specifically, a drug called romosozumab. You might know it by the brand name Evenity. It's been FDA-approved since 2019, it's given as a monthly injection, and it works differently from the osteoporosis drugs most people have heard of. Older drugs like bisphosphonates — think Fosamax — work mostly by slowing down the cells that break bone down. Romosozumab does something on top of that: it also activates the cells that build new bone. It's a dual action, which is why it attracted a lot of attention when it came out.

A new study published this week in the journal Osteoporosis International looked at real-world data — meaning not a controlled clinical trial, but actual patients at high fracture risk who were prescribed romosozumab and then monitored with two different types of scans. Standard DXA scans, which measure bone density, and something called HR-pQCT, which is a much higher-resolution scan that can actually look at bone structure — the architecture, not just the density number.

What they found was that women showed improvements at both the spine and the wrist. That wrist finding is worth pausing on, because the wrist is often the first place a fracture happens when bone loss is serious. It's the hand you throw out when you fall. And the HR-pQCT data suggested the structural quality of the bone was improving, not just the density number on a standard scan. Those are different things. A bone can have okay density but poor internal structure, and that makes it more fragile than the number alone suggests.

Now — this is a real-world study, which means there's no control group. Everyone in the study got the drug. So you can't draw a clean line and say "this drug caused these improvements and nothing else did." That's a real limitation. The researchers acknowledge it. But real-world evidence has its own value: it tells you what happens when the drug moves out of the controlled trial setting and into actual clinical practice, with actual patients who have other health conditions and aren't being monitored every five minutes by a research team. The fact that the results track with what clinical trials showed is reassuring.

My honest read: romosozumab is a serious drug — it carries a black box warning about cardiovascular risk, which means it's not appropriate for women who've had a recent heart attack or stroke. That's not a footnote. That's a real constraint. But for women who are at genuinely high fracture risk and don't have that cardiovascular history, this is the kind of evidence your doctor would look at on a tool like OpenEvidence — peer-reviewed, real-world, and showing structural bone improvement, not just a number moving on a scan. If you're in the high-risk category and no one's mentioned this drug to you, that's worth bringing up.

The bigger frustration I have is that bone health in menopause is chronically under-addressed until someone breaks something. Women aren't routinely told that estrogen is part of what keeps bones dense, and that when estrogen drops, bone loss accelerates — sometimes fast. By the time a fracture happens, years of bone thinning have already occurred. Romosozumab being available is good. More women knowing to ask about their bone health before it becomes a crisis would be better.

Brain structure is the second thing worth talking about today.

A study out of the Netherlands, published this week, used MRI data to look at brain structure across three hormonal transition points in women's lives: puberty, pregnancy, and menopause. They were trying to understand whether these transitions leave visible marks on the brain — and if so, whether those marks overlap or whether each transition does something distinct.

The answer, interestingly, is both. Some structural changes appeared in more than one of the three transitions, suggesting these shifts share some underlying biology. But menopause also produced changes that were specific to it — not seen in puberty or pregnancy. The researchers are careful not to frame these as damage. The word they use is "restructuring," which is a more neutral way to describe the brain reorganizing itself in response to changing hormone levels.

This matters because there's a lot of anxiety — understandable anxiety — around phrases like "menopause brain" or the cognitive changes women describe: the word-finding hiccups, the brain fog, the feeling that their thinking has shifted. What this research is adding to that picture is a biological substrate. Something is actually happening in the brain. It's not imaginary, it's not just stress, it's not just poor sleep (though poor sleep doesn't help). There are structural changes visible on a scan.

What the study does NOT tell us is what those changes mean for function over time — whether they're associated with better or worse cognitive outcomes, whether they're temporary or lasting, or whether things like HRT affect them. Those are the follow-up questions, and we don't have the answers yet. But this kind of foundational imaging research is what makes the follow-up questions askable. You have to see the thing before you can study what it does.

I'll say this plainly: we have decades of research on how male brains age. Research on how female brains move through hormonal transitions is genuinely newer and still catching up. Studies like this one are part of closing that gap. They're not the final word — they're the beginning of a more complete conversation.

The third study is the one I keep thinking about, and it's about voice.

Testosterone is increasingly being prescribed to women — primarily for low libido and low energy, sometimes as part of broader hormone therapy. It's not FDA-approved for women in the United States for those purposes, which means it's prescribed off-label, which means the prescribing landscape is more variable and less standardized than it would be for an approved indication. That matters for what comes next.

A survey published this week looked at prescribers who give testosterone to cisgender women, and at voice clinicians — speech-language pathologists and laryngologists — who treat voice problems. The question was essentially: are prescribers warning their patients that testosterone can change the voice?

The findings are uncomfortable. A significant portion of prescribers were not routinely discussing voice changes as a risk. And voice clinicians reported seeing patients — women who had been on testosterone therapy — who said they were never told this was possible.

Here's why that's a problem. Voice changes from testosterone in women can include a lower pitch, a rougher quality, a loss of range at the top of the voice. And unlike some other side effects that reverse when you stop the medication, voice changes may not fully reverse. The vocal cords can thicken in response to testosterone, and that structural change doesn't always undo itself when the hormone is discontinued. This is well-documented in the transgender medicine literature, which is where a lot of the early data on testosterone and voice in female bodies comes from. It's not a fringe finding.

This is a straightforward informed consent problem. If a woman goes to a prescriber, says she's been exhausted and her libido has tanked, and is offered testosterone as a solution, she has a right to know that one possible outcome is a voice she didn't choose and can't necessarily change back. That's not a reason to categorically avoid testosterone — it may be the right choice for some women. But it's a reason to have the full conversation before starting.

The survey also found that when voice was discussed, it was often framed as a cosmetic concern rather than a functional one. And a voice is not just aesthetic. It's how you communicate at work, how you sound to your kids, how you present yourself in every conversation you have for the rest of your life. Dismissing it as cosmetic is a failure to take it seriously.

What this study is really surfacing is a gap between how quickly prescribing practices have expanded and how slowly the informed consent frameworks have caught up. Off-label prescribing isn't inherently wrong — a lot of important medicine happens off-label. But it does put more responsibility on individual prescribers to know the side effect profile and communicate it, and this survey suggests that's not happening consistently enough.

If you're considering testosterone therapy, or you're already on it and no one mentioned this to you — ask. Ask specifically about your voice. Ask what changes are possible, at what doses, and what the evidence says about reversibility. You're entitled to that information upfront.

---

Episode produced by Hot Flasher. For educational purposes only — not medical advice. Talk to your healthcare provider about your individual situation.

---

Sources curated automatically by the Hot Flasher pipeline.